Scolaro, Michael J.,Sullivan, Sean M.,Gieseler, Robert K.,Hozsa, Constantin,Furch, Marcus
申请号：
AU2016298606
公开号：
AU2016298606A1
申请日:
2016.07.27
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
The present invention relates to the targeted delivery of the active generic antiproliferative and anti-inflammatory agents gemcitabine, paclitaxel and/or curcumin preferentially or exclusively to antigen-presenting cells (APCs) of the immune system by means of encapsulation into a lipid-based nanocarrier, the CLR-TargoSphere, which is surface-labeled with a Fucose-derivative ligand that exclusively targets C-type lectin receptors (CLRs) on APCs to deliver the active agents intracellularly to myeloid dendritic cells (mDCs), circulating monocytes, macrophages, and tumor-associated macrophages (TAMs) as well as cytotoxic T lymphocytes (CTLs).
